Natco gets CDSCO nod for emergency use of Baricitinib tablets for COVID-19 treatment
The Hindu
Baricitinib in combination with Remdesivir, is used for treatment of COVID-19 positive patients, the Natco Pharma said
Drug major Natco Pharma on May 3 said it has received emergency use approval for Baricitinib tablets, for the treatment of COVID-19 positive patients, from the Central Drugs Standard Control Organization (CDSCO) in India. CDSCO is responsible for approval of drugs, conduct of clinical trials, laying down the standards for drugs, control over the quality of imported drugs in the country and coordination of the activities of state drug control organisations. “Natco Pharma Ltd. has received emergency use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organisation (CDSCO) in India,” the company said in a regulatory filing.More Related News

Insurance penetration and density are often misunderstood and do not reveal how many families are insured or whether they would be financially secure if the main earning member were to die. The real issue is not reach but adequacy, as households may have life insurance but not enough cover to replace lost income, leaving them financially vulnerable.












